CD47 and neoplasm: Therapeutics targeting the CD47/SIRPα axis demonstrated anti-tumor efficacy both in vitro and in vivo in preclinical models and are currently being evaluated in clinical trials for both solid and haematologic malignancies as single agents and as combination therapies with tumor-opsonizing mAbs [4,43,126,127,141,142,143].